Member Info for daveycaferacer

Companies sign cda's and nda's every day, if they had to announce it to the market some larger companies would be issuing dozens of RNS's on a daily basis!

At this stage it is not material and as the CEO has stated, big pharma will need to see the final P2 data in 2021

They are not still in discussions, the CEO said on Friday they have signed them already with more than one party.

As I said, and I have legal knowledge :o-) the terms of the Cda probably not only had a non revelare clause, it would have bound both patties to essentially say nothing at all at this stage. It will also probably be time limited as most cda and nda’s are.

So the fact the Company has not issued annRNS to the market is perfectly appropriate.

they can't say anything about any approaches, it will be in the terms of the confidentiality agreement as a non revelare clause

https://www.barchart.com/stocks/quotes/TLSA/opinion
https://www.barchart.com/stocks/quotes/TILS.LN/opinion

This site is useful as it tracks the number of holders of a specific stock - clearly this is still a very niche holding for a small number of Institutional Companies

https://robintrack.net/symbol/HCM

This site is useful as it tracks the number of holders of a specific stock - you can see what's happened in the last few months, and there was a significant rise yesterday. In the U.S. small Biotech's live and die on news as the herd arrive...

https://robintrack.net/symbol/TLSA

i've been on Stocktwits for around 5 years, all very entertaining, and yes people post and buy TLSA thinking it is $TSLA but I've persuaded a couple to stay invested ;o-)

here is a summary on how the ADR programs work for London listed shares:-

When you instruct your broker to buy ordinary shares on your behalf, your broker will have the option of buying shares on AIM, or buying Nasdaq listed ADRs. Conversely, when you wish to sell your position, your broker will either sell them on AIM, or otherwise, may sell them on the Nasdaq market. Any necessary conversion of securities would first be effected in the manner described above. In any event, this would be a seamless process for shareholders. Unless they particularly wish to give specific instructions in that regard (in which case they are free to do so) shareholders will not need to be concerned with which market their shares are purchased from or sold into. Brokers will simply buy or sell in the market where there is the most liquidity at that time.

average = 380k
Current as at 13:15 = 1.1 million

stunning volume of ADR's being traded and some of these trades will be settled with Ordinary shares, even though the London market is closed, which is how the ADR program functions.

correction, now £1.28, this will impact here before the close

£1.17 equivalent being paid stateside y'all

https://stockinvest.us/technical-analysis/TLSA?utm_source=stocktwits&utm_medium=autopost

Tiziana Life Sciences PLC lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. A break down the bottom trend line at $5.65 will firstly indicate a slower rising rate, but may also be a early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 204.65% during the next 3 months and, with 90% probability hold a price between $17.22 and $24.23 at the end of this period.

"I've been approached by Big Pharma"

"Im already under cda with them"

In other words, we have signed confidential disclosure agreements with Big Pharma, this is going to be huge for the entire antibody industry and the CEO has confirmed today talks with large Pharma have started

Tils may not sell the asset/technology - they could instead licence it and get royalties for its use

Abbvie must surely be interested in acquiring this patent (Company) for possible use with anti-CD3 monoclonal antibodies (mAb) including the world's biggest selling drug - Humira

I certainly make any purchases of both ADR's and Ordinary shares after 3.30pm UK time

The price of ADR's almost always drops in the first 1 - 2 hrs of trading

U.S. Pre-market rise driving a big rise here in London for HCM - at last we get some market reaction to some good news

If we'd had similar reactions to more material news recently we'd be much higher now

I continue to Buy

Here is further evidence that StemprintER spin-off is being worked. The following was posted last night at Companies House and shows items being prepared. They will be posted within 5 days so we can expect an RNS very shortly with dates for the AGM/EGM and a record date for the in-specie shares in the new Accustem

https://beta.companieshouse.gov.uk/company/03508592/filing-history

Resolutions
Resolution of allotment of securities
Resolution of removal of pre-emption rights
Replacement option grants 06/05/2020
Resolution of adoption of Articles of Association
This document is being processed and will be available in 5 days.
Memorandum and Articles of Association
This document is being processed and will be available in 5 days.

Great news today on Fruquintinib in the United States in CRC and Fast Track Designation. Great for patients and investors given the CRC revenues outside China are forecast at circa $565m peak sales and the Company owns all rights to Fruquintinib worldwide, outside of China.

What a surprise, appears Duncan MacDonald resgisters Co. names and domain names to, then sells them

https://sedo.com/search/details/?partnerid=14460&language=us&domain=accustemsciences.com&origin=parking&utm_medium=Parking&utm_campaign=template&utm_source=3004